» Articles » PMID: 35335909

Lipid Nanoparticles As a Promising Drug Delivery Carrier for Topical Ocular Therapy-An Overview on Recent Advances

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2022 Mar 26
PMID 35335909
Authors
Affiliations
Soon will be listed here.
Abstract

Due to complicated anatomical and physical properties, targeted drug delivery to ocular tissues continues to be a key challenge for formulation scientists. Various attempts are currently being made to improve the in vivo performance of therapeutic molecules by encapsulating them in various nanocarrier systems or devices and administering them via invasive/non-invasive or minimally invasive drug administration methods. Biocompatible and biodegradable lipid nanoparticles have emerged as a potential alternative to conventional ocular drug delivery systems to overcome various ocular barriers. Lipid-based nanocarrier systems led to major technological advancements and therapeutic advantages during the last few decades of ocular therapy, such as high precorneal residence time, sustained drug release profile, minimum dosing frequency, decreased drug toxicity, targeted site delivery, and, therefore, an improvement in ocular bioavailability. In addition, such formulations can be given as fine dispersion in patient-friendly droppable preparation without causing blurred vision and ocular sensitivity reactions. The unique advantages of lipid nanoparticles, namely, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, and liposomes in intraocular targeted administration of various therapeutic drugs are extensively discussed. Ongoing and completed clinical trials of various liposome-based formulations and various characterization techniques designed for nanoemulsion in ocular delivery are tabulated. This review also describes diverse solid lipid nanoparticle preparation methods, procedures, advantages, and limitations. Functionalization approaches to overcome the drawbacks of lipid nanoparticles, as well as the exploration of new functional additives with the potential to improve the penetration of macromolecular pharmaceuticals, would quickly progress the challenging field of ocular drug delivery systems.

Citing Articles

Nanoparticles in intraocular drug delivery.

Klaus S, Breunig M, Gopferich A Med Genet. 2025; 37(1):37-46.

PMID: 39943986 PMC: 11812474. DOI: 10.1515/medgen-2024-2058.


Exploring the landscape of Lipid Nanoparticles (LNPs): A comprehensive review of LNPs types and biological sources of lipids.

Alfutaimani A, Alharbi N, Alahmari A, Alqabbani A, Aldayel A Int J Pharm X. 2024; 8:100305.

PMID: 39669003 PMC: 11635012. DOI: 10.1016/j.ijpx.2024.100305.


Recent Advances in Ocular Drug Delivery: Insights into Lyotropic Liquid Crystals.

Adwan S, Qasmieh M, Al-Akayleh F, Ali Agha A Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458956 PMC: 11509982. DOI: 10.3390/ph17101315.


Innovations in Nanoemulsion Technology: Enhancing Drug Delivery for Oral, Parenteral, and Ophthalmic Applications.

Jacob S, Kather F, Boddu S, Shah J, Nair A Pharmaceutics. 2024; 16(10).

PMID: 39458662 PMC: 11510719. DOI: 10.3390/pharmaceutics16101333.


SLNs and NLCs for Skin Applications: Enhancing the Bioavailability of Natural Bioactives.

Safta D, Bogdan C, Moldovan M Pharmaceutics. 2024; 16(10).

PMID: 39458602 PMC: 11510141. DOI: 10.3390/pharmaceutics16101270.


References
1.
Patel N, Nakrani H, Raval M, Sheth N . Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability. Drug Deliv. 2016; 23(9):3712-3723. DOI: 10.1080/10717544.2016.1223225. View

2.
Lai S, Wei Y, Wu Q, Zhou K, Liu T, Zhang Y . Liposomes for effective drug delivery to the ocular posterior chamber. J Nanobiotechnology. 2019; 17(1):64. PMC: 6515668. DOI: 10.1186/s12951-019-0498-7. View

3.
Wadhwa J, Nair A, Kumria R . Emulsion forming drug delivery system for lipophilic drugs. Acta Pol Pharm. 2012; 69(2):179-91. View

4.
Couto Pires V, Magalhaes C, Ferrante M, de Souza Reboucas J, Nguewa P, Severino P . Solid lipid nanoparticles as a novel formulation approach for tanespimycin (17-AAG) against leishmania infections: Preparation, characterization and macrophage uptake. Acta Trop. 2020; 211:105595. DOI: 10.1016/j.actatropica.2020.105595. View

5.
Beloqui A, Solinis M, Rodriguez-Gascon A, Almeida A, Preat V . Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine. 2015; 12(1):143-61. DOI: 10.1016/j.nano.2015.09.004. View